The Widening Gulf in Pharmaceutical Dealmaking
The pharma-to-biotech dealmaking drought, which began in 1999, continues in 2000. Drug companies have been distracted by consolidation and by their focus on later-stage products; biotechs have found funding through the capital markets. Instead, there have been plenty of biotech-to-biotech deals--little cash changes hands, but each partner's technology enables the other to reach later-stages of development, and thus keep a higher proportion of the drug's upside, granted the other has the cash to develop it.
You may also be interested in...
Manufacturers Should Map Processes, Bolster Quality Culture To Tackle Data Integrity Problems in The Microbiology Lab
To reduce the opportunity for data integrity failures in the microbiology lab, manufacturers should map out the workflow so that activities and expectations for employees are clearly spelled out. Having formalized processes will ensure that employees don’t cut corners.
Companies can have their EU centralized marketing authorization application and submission for an Article 58 opinion (on medicines for use in non-EU countries) reviewed in parallel by the European Medicines Agency. The simultaneous assessment can be helpful when drugs and vaccines are needed for both EU and non-EU populations.
The coronavirus could have serious adverse effects on regulatory procedures at both European Medicines Agency and EU member state level. A new business continuity plan describes how procedures will be prioritized if problems arise.